Biomarkers Definitions Working Group. 2001. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clinical Pharmacology and Therapeutics 69(3):89–95.
IOM (Institute of Medicine). 2007. Cancer biomarkers: The promises and challenges of improving detection and treatment. Washington, DC: The National Academies Press.
Schneeman, B. 2007. FDA's review of scientific evidence for health claims. Journal of Nutrition 137(2):493–494.
Wagner, J. A. 2002. Overview of biomarkers and surrogate endpoints in drug development. Disease Markers 18(2):41–46.
The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease . Washington, DC: The National Academies Press,
Please select a format: